Table 4.
All-cause rehospitalization vs. no rehospitalization in relation to 180-day all-cause death
| Risk factor | Multivariable
|
||
|---|---|---|---|
| HR (95% CI) | SE | P-value | |
| Any rehospitalization vs. no rehospitalization | 2.38 (1.93–2.94) | 0.108 | <0.001 |
| History of cerebrovascular disease | 1.51 (1.20–1.90) | 0.118 | 0.001 |
| Chronic respiratory disease | 1.19 (0.95–1.49) | 0.115 | 0.130 |
| Prior CRT (with or without ICD) | 0.83 (0.61–1.12) | 0.153 | 0.212 |
| Baseline heart rate, per 5 b.p.m. | 1.00 (0.98–1.03) | 0.003 | 0.861 |
| Current smoker vs. never smoked | 0.79 (0.59–1.07) | 0.153 | 0.123 |
| Past smoker vs. never smoked | 0.96 (0.80–1.17) | 0.098 | 0.706 |
| Chronic loop diuretic use | 1.93 (1.53–2.43) | 0.118 | <0.001 |
| Hospitalization in last year | 1.23 (1.02–1.48) | 0.095 | 0.027 |
| Asia Pacific vs. North America | 0.74 (0.57–0.97) | 0.138 | 0.029 |
| Central Europe vs. North America | 0.68 (0.48–0.95) | 0.173 | 0.024 |
| Latin America vs. North America | 1.22 (0.90–1.65) | 0.153 | 0.198 |
| Western Europe vs. North America | 1.18 (0.84–1.66) | 0.174 | 0.337 |
| Hydralazine use | 0.89 (0.64–1.25) | 0.173 | 0.504 |
| Baseline sodium, per 5 mmol/L | 0.81 (0.73–0.88) | 0.010 | <0.001 |
| Digoxin use | 1.15 (0.95–1.39) | 0.097 | 0.156 |
| Orthopnoea | 0.84 (0.69–1.03) | 0.104 | 0.093 |
| Oral/topical nitrate use | 1.11 (0.90–1.36) | 0.104 | 0.325 |
| Baseline weight < 85 kg, per 5 kg | 0.92 (0.88–0.96) | 0.004 | <0.001 |
| Baseline weight ≥85 kg, per 5 kg | 0.96 (0.92–0.99) | 0.004 | 0.015 |
CI, confidence interval; CRT, cardiac resynchronization therapy; HR, hazard ratio; ICD, implantable cardioverter defibrillator; SE, standard error.